Back to search

France· FR:60726849

AMISULPRIDE ARROW LAB 200 mg, comprimé sécable

A amisulpride product containing amisulpride, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC N05AL05

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedAMISULPRIDE ARROW LAB 200 mg, comprim…ATCN05AL05REGISTER NO.FR:60726849PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Amisulpride is registered in 14 of 19 countries.

Countries holding a registration under ATC N05AL05 (amisulpride), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Amisulpride · ATC N05AL05

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of amisulpride costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $1.37 in France to $2.49 in Switzerland — a ×1.8 gap.

  • France: $1.37 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Amisulpride · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$2.49
  • IT Italy$1.87
  • FR France$1.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
AMISULPRIDE
Manufacturer
ARROW GENERIQUES
Country
France (FR)
ATC code
N05AL05
ATC class
Amisulpride
Defined daily dose
0.4 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930193792
    plaquette(s) PVC aluminium de 60 comprimé(s)
    EUR 36.22

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

228 interactions on record for amisulpride.

Graded by severity as the source publishes them — 126 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Amisulpride · interactions on record

228 records

  • 126 severe
  • 49 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe

51 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Amisulpride in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amisulpride products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Amisu, Solian
  • Belgium · Amisulpride Eg, Solian
  • Bulgaria · Alonet, Медосулпид
  • Cyprus · Aktiprol, Solian
  • Czechia · Aktiprol, Amilia
  • Germany · Amisulprid Aaa, Amisulprid Mylan
  • Denmark · Aktiprol, Amisulprid Dlf
  • Estonia · Amisan, Solian
  • Spain · Amisulprida Aurovitas, Amisulprida Normon
  • United Kingdom (Northern Ireland) · Amisulpride, Amisulpride Accord-Uk
  • Greece · Isofredil, Nodasic
  • Croatia · Aktiprol, Solian
  • Hungary · Amisulprid Ratiopharm, Amitrex
  • Ireland · Amisulpride Mylan, Solian
  • Iceland · Solian
  • Italy · Amisulpride Aurobindo, Amisulpride Doc
  • Lithuania · Aktiprol, Amisan
  • Luxembourg · Amisulpride Eg, Solian
  • Latvia · Aktiprol, Solian
  • Malta · Aktiprol, Amisulpride Syri Pharma
  • Netherlands · Aktiprol
  • Norway · Solian
  • Poland · Amipryd, Amisan
  • Portugal · Amissulprida Aurobindo, Amissulprida Aurovitas
  • Romania · Masultab, Midora
  • Slovenia · Solian
  • Slovakia · Aktiprol, Amisulprid Viatris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dc36ebe8-20d3-49a6-923f-86d6059db60d
GET /v1/drugs/dc36ebe8-20d3-49a6-923f-86d6059db60d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60726849",
  "date_amm": "2019-11-22",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "AMISULPRIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé sécable",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about amisulpride.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.